Fevronia Foivi Megalofonou

Fat metabolism

As a physician in training in obstetrics and a research physician in dyslipidemia at the Friede Springer - Cardiovascular Prevention Center, I have the privilege of deepening my expertise in two important medical disciplines. Early on, it was important to me to combine my work with continuous education and research in order to become not only a dedicated obstetrician, but also a good physician and researcher who uses her knowledge in a multidisciplinary way for the benefit of people.

At FS-CPC, our focus is on early detection and innovative interventions for the prevention and treatment of cardiovascular diseases. Familial hypercholesterolemia in particular, one of the most common lipid metabolism disorders worldwide, represents a significant cardiovascular risk factor. Despite its importance, it is still often underdiagnosed and inadequately treated, especially in the first years of life.

Our work goes one step further - or rather, one step back - into the mother's womb. Early detection and prevention begin during fetal development. By closely accompanying women during pregnancy and examining their newborns immediately after birth, we aim to identify affected pregnant women and their newborns at an early stage and establish the need for newborn screening for familial hypercholesterolemia as a new standard in routine diagnostics.

The ultimate goal of cardiovascular disease prevention is to identify risks early before they lead to pathological changes in our bodies. It is with great enthusiasm that I am willing to research the connections between cardiovascular risks during pregnancy and the resulting risk factors in newborns at the FS-CPC.